Study Summary
This study is a Phase I trial using an advanced lentiviral vector to deliver a functional gene for human clotting factor VIII into patients with hemophilia A, to evaluate the safety and efficacy of infusion of lentiviral gene modified autologous stem cells in patients.
Interested in this trial?
Submit an InquiryInterventions
YUVA-GT-F801BIOLOGICAL
Lentiviral factor VIII gene modified autologous hematopoeitic stem cells and mesenchymal stem cells
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Shenzhen Geno-immune Medical Institute | Shenzhen | Guangdong | China |